475 related articles for article (PubMed ID: 21278443)
1. Directed therapy of subtypes of triple-negative breast cancer.
Carey LA
Oncologist; 2011; 16 Suppl 1():71-8. PubMed ID: 21278443
[TBL] [Abstract][Full Text] [Related]
2. Directed therapy of subtypes of triple-negative breast cancer.
Carey LA
Oncologist; 2010; 15 Suppl 5():49-56. PubMed ID: 21138955
[TBL] [Abstract][Full Text] [Related]
3. Molecular stratification of triple-negative breast cancers.
Perou CM
Oncologist; 2011; 16 Suppl 1():61-70. PubMed ID: 21278442
[TBL] [Abstract][Full Text] [Related]
4. Molecular stratification of triple-negative breast cancers.
Perou CM
Oncologist; 2010; 15 Suppl 5():39-48. PubMed ID: 21138954
[TBL] [Abstract][Full Text] [Related]
5. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
Kurebayashi J
Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy of triple-negative breast cancer.
Arslan C; Dizdar O; Altundag K
Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic strategies for triple-negative breast cancer.
Tan AR; Swain SM
Cancer J; 2008; 14(6):343-51. PubMed ID: 19060597
[TBL] [Abstract][Full Text] [Related]
8. [Triple-negative breast carcinoma--rewiev of current literature].
Rubovszky G; Udvarhelyi N; Horváth Z; Láng I; Kásler M
Magy Onkol; 2010 Dec; 54(4):325-35. PubMed ID: 21163763
[TBL] [Abstract][Full Text] [Related]
9. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
Venkitaraman R
Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
[TBL] [Abstract][Full Text] [Related]
10. Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer.
Greenberg S; Rugo HS
Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S20-9. PubMed ID: 20805062
[TBL] [Abstract][Full Text] [Related]
11. Promising therapeutic options in triple-negative breast cancer.
Bilici A; Arslan C; Altundag K
J BUON; 2012; 17(2):209-22. PubMed ID: 22740196
[TBL] [Abstract][Full Text] [Related]
12. What is triple-negative breast cancer?
Irvin WJ; Carey LA
Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
[TBL] [Abstract][Full Text] [Related]
13. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.
Perez EA; Patel T; Moreno-Aspitia A
Breast Cancer Res Treat; 2010 Jun; 121(2):261-71. PubMed ID: 20229176
[TBL] [Abstract][Full Text] [Related]
15. Metastatic triple-negative breast cancer.
Rakha EA; Chan S
Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):587-600. PubMed ID: 21524569
[TBL] [Abstract][Full Text] [Related]
16. Triple-negative breast cancer: role of the androgen receptor.
Gucalp A; Traina TA
Cancer J; 2010; 16(1):62-5. PubMed ID: 20164692
[TBL] [Abstract][Full Text] [Related]
17. Triple negative breast cancer: a brief review of its characteristics and treatment options.
Griffiths CL; Olin JL
J Pharm Pract; 2012 Jun; 25(3):319-23. PubMed ID: 22551559
[TBL] [Abstract][Full Text] [Related]
18. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy for triple-negative breast cancer: where are we?
Duffy MJ; McGowan PM; Crown J
Int J Cancer; 2012 Dec; 131(11):2471-7. PubMed ID: 22581656
[TBL] [Abstract][Full Text] [Related]
20. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]